Compare PLAB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | BCYC |
|---|---|---|
| Founded | 1969 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 516.8M |
| IPO Year | 1987 | 2019 |
| Metric | PLAB | BCYC |
|---|---|---|
| Price | $36.73 | $7.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $43.50 | $18.73 |
| AVG Volume (30 Days) | ★ 1.8M | 293.3K |
| Earning Date | 12-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $849,294,000.00 | $28,339,000.00 |
| Revenue This Year | $4.63 | N/A |
| Revenue Next Year | $6.20 | N/A |
| P/E Ratio | $15.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.46 | $6.03 |
| 52 Week High | $39.80 | $21.14 |
| Indicator | PLAB | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 78.97 | 52.53 |
| Support Level | $35.69 | $7.03 |
| Resistance Level | $39.80 | $7.65 |
| Average True Range (ATR) | 1.61 | 0.37 |
| MACD | 1.71 | 0.08 |
| Stochastic Oscillator | 83.24 | 53.12 |
Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz or glass plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue world-wide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.